This difference is related to the onset of the postzygotic somatic mutation with activation of the mTOR pathway.13, 14 Thus, the characterization of variants in mTOR pathway genes raises the possibility that mTOR inhibitors could have wider therapeutic benefit for patients with focal epilepsy.7 This evidence concerns the gene MTOR and focal epilepsy.